Abstract
There is a lack of emphasis on health-related QOL (HR-QOL) changes associated with acute exacerbation of chronic bronchitis (CB) or chronic obstructive pulmonary disease (COPD). The aim of this review is to examine the use of HR-QOL instruments to evaluate acute exacerbation of CB or COPD, so as to form recommendations for future research.
A literature search of papers published between 1966 and July 2003 identified more than 300 articles that used acute exacerbation of CB or COPD as the search term. However, only 21 of these studies employed HR-QOL measures as predictors of outcome or in the assessment of the impact, evolution or treatment of acute exacerbations of COPD or CB. A variety of HR-QOL measures were used, both generic and disease specific. The disease-specific St George’s Respiratory Questionnaire (SGRQ), devised for patients with stable CB and with a recall period of 1–12 months, was the most widely used measure, with the Chronic Respiratory disease Questionnaire (CRQ) and the Baseline and Transitional Dyspnoea Index (BDI, TDI) being the only other disease-specific measures used.
Most measures, both generic and disease specific, performed adequately when used during acute exacerbation of CB or COPD and indicated poor HR-QOL during acute exacerbation, which improved on resolution of the exacerbation. Relationships were evident between HR-QOL during an acute exacerbation and various outcomes, including post-exacerbation functional status, hospital readmission for acute exacerbation or COPD, and mortality.
There is a need for studies of treatments for acute exacerbation of CB or COPD to include an appropriate HR-QOL instrument to aid in the stratification of patients so as to target the right treatment to the right patient group. While a new instrument could be developed to measure HR-QOL during acute exacerbation of CB or COPD, currently available disease-specific measures such as the CRQ and the SGRQ appear to be acceptable to patients during acute exacerbation. However, the recall period of the SGRQ symptoms component should be shortened to make it more appropriate for use during acute exacerbation.
Similar content being viewed by others
References
Ball P, Harris JM, Lowson D, et al. Acute infective exacerbations of chronic bronchitis. Q J Med 1995; 88: 61–8
Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418–22
Miravitlles M, Guerrero T, Mayordomo C, et al. on behalf of the EOLO Study Group. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. Respiration 2000; 67: 495–501
Garibaldi RA. Epidemiology of community acquired respiratory tract infections in adults: Incidence, etiology and impact. Am J Med 1995; 78: 32–7
Burrows B, Earle RH. Course and prognosis of chronic obstructive lung disease: a prospective study of 200 patients. N Engl J Med 1969; 280: 397–404
Miravitlles M, Murio C, Guerrero T, et al. for the DAFNE Study Group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121 (5): 1449–55
Skrepnek GH, Skrepnek SV. Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma. Am J Manag Care 2004; 10: S129–38
Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease stage and health related quality of life. Ann Intern Med 1997; 127: 1072–9
Schlenk EA, Erlen JA, Dunbar-Jacob J, et al. Health-related quality of life in chronic disorders: a comparison across studies using the MOS SF-36. Qual Life Res 1998; 7: 57–65
Moody L, McCormick K, Williams AR. Psychophysiologic correlates of quality of life in chronic bronchitis and emphysema. West J Nurs Res 1991; 13: 336–62
Curtis JR, Deyo RA, Hudson LD. Health-related quality of life among patients with chronic obstructive pulmonary disease. Thorax 1994; 49: 162–70
Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645–8
Miravidles M, Ferrer M, Pont A, et al. for the IMPACT study group. Exacerbations impair quality of life in patients with chronic obstructive pulmonary disease: a two-year follow-up study. Thorax 2004; 59: 387–95
Nicolson P, Anderson P. The patient’s burden: physical and psychological effects of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 2000; 45: 25–32
Lehnert H, Schuster H-P. Innere medizin. Stuttgart: Ferdinand Enke Verlag, 1998
Kanner RE, Anthonisen NR, Connet JE. Lower respiratory illnesses promote FEV t decline in current smokers but not exsmokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 358–64
Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–52
Curtis JR, Martin DP, Martin TR. Patient-assessed health outcomes in chronic lung disease: what are they, how do they help us, and where do we go from here? Am J Respir Crit Care Med 1997; 156: 1032–9
Ketelaars CAJ, Schlosser MAG, Mostert RT, et al. Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 39–43
Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283–9
McSweeney AJ, Heaton RK, Grant I, et al. Chronic obstructive pulmonary disease: socioemotional adjustment and quality of life. Chest 1982; 77: 309–11
Okubadejo AA, Jones PW, Wedzicha JA. Quality of life in patients with chronic obstructive pulmonary disease and severe hypoxemia. Thorax 1996; 51: 44–7
Aaron SD, Vandemheen KL, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003; 348: 2618–25
Aaron SD, Vandemheen KL, Clinch JJ, et al. Measurement of short-term changes in dyspnoea and disease-specific quality of life following an acute COPD exacerbation. Chest 2002; 121 (3): 688–96
Almagro P, Calbo E, de Echagden AO, et al. Mortality after hospitalisation for COPD. Chest 2002; 121: 1441–8
Andersson I, Johansson K, Larsson S, et al. Long-term oxygen therapy and quality of life in elderly patients hospitalised due to severe exacerbation of COPD: a 1 year follow-up study. Respir Med 2002; 96: 944–9
Anie K, Lowton K, Jones PW. Changes in health status following an acute infective exacerbation of COPD [abstract]. Fur Respir J 1997; 10: 148S
Behnke M, Taube C, Kirsten D, et al. Home-based exercise is capable of preserving hospital-based improvements in severe chronic obstructive pulmonary disease. Respir Med 2000; 94: 1184–91
Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 154: 959–67
Davies L, Wilkinson M, Bonner S, et al. “Hospital at home” versus hospital care in patients with exacerbations of chronic obstructive pulmonary disease: prospective randomised controlled trial. BMJ 2000; 321: 1265–8
Dellamonica P, Reman A, Chiche D, et al. Traitement des exacerbations des bronchitis chroniques: c6furoxime IM avec relais per os par c6furoxime axetil versus ceftriaxone IM. Med Mal Infect 1997; 27: 294–300
Doll H, Grey-Amante P, Duprat-Lomon I, et al. Quality of life in acute exacerbation of chronic bronchitis: results from a German population study. Respir Med 2002; 96: 39–51
Doll H, Duprat-Lomon I, Ammerman E, et al. Validity of the St George’s respiratory questionnaire at acute exacerbation of chronic bronchitis: comparison with the Nottingham health profile. Qual Life Res 2003; 12: 117–32
Garcia-Aymerich J, Farrero E, Félez MA, et al. Risk factors of re-admission to hospital for a COPD exacerbation: a prospective study. Thorax 2003; 58: 100–5
Grossman R, Mukhegjee J, Vaughan D, et al. for the Canadian Ciprofloxacin Health Economic Study Group. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 1998; 113 (7): 131–41
Lorenz J, Thate-Waschke IM, Mast O, et al. Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective. J Int Med Res 2001; 29: 74–86
Lynn J, Ely W, Zhong Z, et al. Living and dying with chronic obstructive pulmonary disease. J Am Geriatr Soc 2000; 48: S91–S100
Osman LM, Godden DJ, Friend JAR, et al. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997; 52: 67–71
Patterson C, Langan CE, McKaig GA, et al. Assessing patient outcomes in acute exacerbation of chronic bronchitis: the measure your medical outcome profile (MYMOP), medical outcomes study 6-item general health survey (MOS-6A) and EuroQoL (EQ-5D). Qual Life Res 2000; 9: 521–7
Saundy-Unterberger H, Martin JG, Gray-Donald K. Impact of nutritional support on functional status during an acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 794–9
Schouenborg P, Gerdes N, Rasmussen HH, et al. Azithromycin versus pivampicillin in the treatment of acute exacerbations of chronic bronchitis: a single-blind, double-dummy, multicentre study. J Int Med Res 2000; 28: 101–10
Seneff MG, Wagner DP, Wagner RP, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995; 274: 1852–7
Spencer S, Jones PW, for the GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58: 589–93
Bach PB, Brown C, Gelfand SE, et al. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 2001; 134 (7): 600–20
Blanchard AR. Treatment of COPD exacerbations: pharmacologic options and modification of risk factors. Postgrad Med 2002; 111 (6): 65–8, 71-2, 75
Calverley PMA. Modern treatment of chronic obstructive pulmonary disease. Fur Respir J 2001; 18 Suppl. 34: 60S–6S
Camargo CA. The relationship between COPD exacerbations and other outcomes. Fur Respir Rev 2002; 12: 9–10
Morris S, Anderson P, Irwin DE. Acute exacerbations of chronic bronchitis: a pharmacoeconomic review of antibacterial use. Pharmacoeconomics 2002; 20 (3): 153–68
Perfetto EM, Mullins CD, Subedi P, et al. Selection of clinical, patient-reported, and economic end points in acute exacerbation of chronic bronchitis. Clin Ther 2001; 23 (10): 1747–72
Sohy C, Pilette C, Niederman MS, et al. Acute exacerbation of chronic obstructive pulmonary disease and antibiotics: what studies are still needed? Fur Respir J 2002; 19: 966–75
Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation: the St George’s Respiratory Questionnaire. Respir Med 1991; 85: 2531
Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Fur Respir J 2002; 19: 398–404
Jaeschke R, Singer J, Guyatt GH. Measurement of health status ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407–15
Peach H, Pathy MS. Follow-up study of disability among elderly patients discharged from hospital with exacerbations of chronic bronchitis. Thorax 1981; 36: 585–9
Wu AW, Damiano AM, Lynn J, et al. Predicting future functional status for seriously ill hospitalised adults. The SUPPORT prognostic model. Ann Intern Med 1995; 122: 342–50
Smucny JJ, Becker LA, Glazier RH, et al. Are antibiotics effective treatment for acute bronchitis? A meta-analysis. J Fam Pract 1998; 47: 453–60
Leidy NK, Margolis MK, Anton SF, et al. Health-related quality of life effects and outcomes of treatment in patients with COPD. Fur Respir Rev 2002; 12: 83, 79-86
Bowling A. Measuring disease: a review of disease specific quality of life measurement scales. Philadelphia (PA): Open University Press, 2001: 149–74
Chen Y, Breithaupt K, Muhajarine N. Occurrence of chronic obstructive pulmonary disease among Canadians and sexrelated risk factors. J Clin Epidemiol 2000; 53: 755–61
Del Donno M, Olivieri D. Mucoactive drugs in the management of chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 1998 Dec; 53 (6): 714–9
DiLorenzo G, Morici G, Drago A, et al. Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. Clin Ther 1998; 20: 1130–48
Fishman AP. Pulmonary rehabilitation research. Am J Crit Care Med 1994; 149: 825–33
Morgan MDL. Experience of using the CRQ (Chronic Respiratory Questionnaire). Respir Med 1991; 85 Suppl. B: 23–4
Taytard A, Cousson F. Symptoms and life of patients with chronic bronchitis: preliminary results. Rev Pneumol Clin 1996; 52 (6: 379–85
Maille AR, Koning CJ, Zwinderman AH, et al. The development of the Quality of Life for Respiratory Illness Questionnaire (QoL-RIQ): a disease-specific quality of life question naire for patients with mild to moderate chronic non-specific lung disease. Respir Med 1997 May; 91 (5): 297–309
Miravitlles M, Alvarez-Sala JL, Lamarca R, et al. for the IMPAC Study Group. Treatment and quality of life in patients with chronic obstructive pulmonary disease. Qual Life Res 2002; 11: 329–38
Tsukino M, Nishimura K, Ikeda A, et al. Physiologic factors that determine the health-related quality of life in patients with COPD. Chest 1996; 111 (4): 896–903
Seemungal TAR, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1608–13
Niewoehner DE, Collins D, Erbland ML. Relation of FEV(1) to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Coopera tive Study Group. Am J Respir Crit Care Med 2000; 161: 1201–5
Yohannes AM, Room J, Waters K, et al. Quality of life in elderly patients with COPD: measurement and predictive factors. Respir Med 1998; 92: 1231–6
Wegner RA, Jörres RA, Kirsten DK, et al. Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD. Fur Respir J 1994; 7: 725–9
Hajiro T, Nishimura K, Tsukino M, et al. Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1185–9
Jones PW. Health status measurement in COPD. Thorax 2001; 56: 880–7
Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following six months treatment with once daily tiotropium compared to twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399–404
Barr IT, Schumacher GE, Freeman S, et al. American translation, modification, and validation of the St. George’s Respiratory Questionnaire. Clin Ther 2000; 22: 1121–45
Rutten-van Mölken M, Roos B, Van Noord JA. An empirical comparison of the St. George’s Respiratory Questionnaire (SGRQ and the Chronic Respiratory Disease Questionnaire (CRQ in a clinical trial setting. Thorax 1999; 54: 995–1003
Grossman RF. How do we achieve cost-effective options in lower respiratory tract infection therapy? Chest 1998; 113 (3S): 205S–1 OS
Wilson R, Wilson C. Defining subsets of patients with chronic bronchitis. Chest 1997; 112: 303S–9S
Adams SG, Melo J, Luther M, et al. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117 (5): 1345–52
Miravitlles M. Designing future clinical trials for acute exacerbations of chronic bronchitis. In: Allegra L, Blasi F, editors. Mechanisms and management of COPD exacerbations. Milano: Springer-Verlag, 2000: 88–99
Perkins HS. Using outcome predictions to make treatment decisions. Chest 1987; 91: 475–6
Menzies R, Gibbons W, Goldberg P. Determinants of weaning and survival among patient with COPD who require mechanical ventilation for acute respiratory failure. Chest 1989; 95: 398–405
Ortqvist A. Treatment of community-acquired lower respiratory tract infections in adults. Fur Respir J 2002; 20 (36S): 40S–53S
Snow V, Lascher S, Mottur-Pilson C. The evidence base for management of acute exacerbations of COPD. Chest 2001; 119: 1185–9
White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease 6: the aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 2003; 58: 73–80 HR-QOL in Acute Exacerbations of Chronic Bronchitis and COED 363
Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in acute exacerbation of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204
Wilson R, Grossman R. Introduction: the role of bacterial infection in chronic bronchitis. Semin Respir Infect 2000; 15 (1): 16
Miravitlles M. Epidemiology of chronic obstructive pulmonary disease exacerbations. Clin Pulm Med 2002; 9 (4): 1–7
Miravitlles M, Murio C, Guerrero T, et al. on behalf of the DAFNE study group. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. Fur Respir J 2001; 17: 928–33
Asmundsson T, Kilburn KH. Survival after acute respiratory failure: 145 patients observed 5 to 8 and one-half years. Ann Intern Med 1974; 80: 54–7
Burk RH, George RB. Acute respiratory failure in chronic obstructive pulmonary disease: immediate and long-term prognosis. Arch Intern Med 1973; 132: 865–8
Sluiter III, Blokzijl EJ, van Dijl W, et al. Conservative and respirator treatment of acute respiratory insufficiency in patients with chronic obstructive lung disease: a reappraisal. Am Rev Respir Dis 1972; 105: 932–43
Teno JM, Harrell FE, Knaus W, et al. Prediction of survival for older hospitalised patients: the HELP survival model. J Am Geriatr Soc 2000; 48 (5 Suppl.): S16–24
Vandenbergh E, van de Woestlijne KP, Gyslen A. Conservative treatment of acute respiratory failure in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1968; 98: 60–9
Warren PM, Millar IS, Fenley DC, et al. Respiratory failure revisited: acute exacerbations of chronic bronchitis between 1961-1968 and 1970-1976. Lancet 1980; 1: 467–71
Read RC. Infection in acute exacerbations of chronic bronchitis: a clinical perspective. Respir Med 1999; 93: 845–50
Adams SG, Anzueto A. Antibiotic therapy in acute exacerbations of chronic bronchitis. Semin Respir Infect 2000; 15 (3): 234–47
McCrory DC, Brown C, Gelfand SE, et al. Management of acute exacerbations of COPD. Chest 2001; 119: 1190–209
Niederman MS. Antibiotic therapy of exacerbations of chronic bronchitis. Semin Respir Infect 2000; 15 (1): 59–70
Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic pulmonary disease exacerbations: a meta-analysis. JAMA 1995; 273: 957–60
Dewan NA, Rafique S, Kanwar B, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 2000; 117: 662–71
Rowe BH, Oxman AD. Performance of an asthma quality of life questionnaire in an outpatient setting. Am Rev Respir Dis 1993; 148: 675–81
Kanga J, Kuhn R, Craigmyle L, et al. Cystic fibrosis clinical score: a new scoring system to evaluate acute pulmonary exacerbation. Clin Ther 1999; 21 (8): 1343–56
Evans AT, Husain S, Durairaj L, et al. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet 2002; 359: 1648–54
Yohannes AM, Hardy CC. Treatment of chronic obstructive pulmonary disease in older patients: a practical guide. Drugs Aging 2003; 20: 209–28
Acknowledgements
The work was performed at Oxford Outcomes, Old Barn, Jericho Farm, Cassington, Oxford, UK.
The study was funded by Bayer Plc. Marc Miravitlles has served as consultant for Aventis, Bayer, GlaxoSmithKline, Ortho-McNeil and Pfizer.
We are grateful to Bayer Plc who funded this work.
The authors are aware of no potential conflicts of interest that are directly relevant to the content of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Doll, H., Miravitlles, M. Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Pharmacoeconomics 23, 345–363 (2005). https://doi.org/10.2165/00019053-200523040-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200523040-00005